ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.627,57
-0,14%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Immunome Inc (IMNM)

  7. Immunome Inc (IMNM) News

IMNM

Immunome (IMNM)

Immunome Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IMNM
DatumZeitQuelleÜberschriftSymbolFirma
20/05/202414h00Business WireImmunome Announces Completion of Purchase of Assets from AtrecaNASDAQ:IMNMImmunome Inc
17/05/202423h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
17/05/202414h00Business WireImmunome Announces Promotion of Max Rosett to Chief Financial OfficerNASDAQ:IMNMImmunome Inc
14/05/202414h48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
14/05/202414h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNMImmunome Inc
14/05/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
14/05/202414h00Business WireImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNMImmunome Inc
08/05/202414h00Business WireImmunome to Present at 2024 Bank of America Healthcare ConferenceNASDAQ:IMNMImmunome Inc
02/05/202414h00Business WireImmunome Appoints Kinney Horn as Chief Business OfficerNASDAQ:IMNMImmunome Inc
25/04/202414h26Business WireImmunome Appoints Sandra M. Swain to Board of DirectorsNASDAQ:IMNMImmunome Inc
05/04/202414h00Business WireImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IMNMImmunome Inc
28/03/202421h02Business WireImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsNASDAQ:IMNMImmunome Inc
26/03/202413h00Business WireImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaNASDAQ:IMNMImmunome Inc
07/03/202414h00Business WireImmunome to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:IMNMImmunome Inc
01/03/202414h00Business WireImmunome to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:IMNMImmunome Inc
22/02/202403h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
22/02/202403h07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
20/02/202414h15Business WireImmunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsNASDAQ:IMNMImmunome Inc
16/02/202422h05Business WireImmunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:IMNMImmunome Inc
14/02/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
14/02/202422h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
14/02/202404h38Business WireImmunome Announces Pricing of Public Offering of Common StockNASDAQ:IMNMImmunome Inc
13/02/202422h36Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMNMImmunome Inc
13/02/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
13/02/202422h05Business WireImmunome Announces Proposed Public Offering of Common StockNASDAQ:IMNMImmunome Inc
12/02/202420h10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMNMImmunome Inc
06/02/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNMImmunome Inc
05/02/202414h00Business WireImmunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:IMNMImmunome Inc
02/02/202422h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IMNMImmunome Inc
01/02/202402h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNMImmunome Inc
 Showing the most relevant articles for your search:NASDAQ:IMNM

Kürzlich von Ihnen besucht

TG
MBG
MercedesBenz
TG
NOV
Novo Nordisk
TG
RHM
Rheinmetall
NYSE
MCD
McDonalds
NYSE
DIS
Walt Disney
COIN
SOLUSD
Solana
NYSE
MRK
Merck
CCOM
SILVER
SILVER
NASDAQ
GOOGL
Alphabet
TG
LHA
Deutsche Lufthansa
AMEX
XLV
Health Care Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BNPQY
BNP Paribas (QX)
DBI
DAX
DAX
TG
D7G
Nel ASA
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten